Declining ALS Patients Are Waiting On The FDA...

Game apps like High 5 Casino and Monopoly GO! are wildly popular. Players pay up for perks and the mobile game industry makes money – a lot of money. But scrutiny on these kinds of games and what some players call addictive, gambling-like qualities could challenge the way they do ...  Show more

The US government is required to pay back $166 billion in revenue it collected as part of sweeping global tariffs struck down by the Supreme Court earlier this year. On today’s Big Take podcast, host David Gura talks with Bloomberg economics reporter Laura Curtis and a trade expe ...  Show more

ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a co ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

For decades, the law has sought to restrain nursing homes from trying to control the behavior of dementia patients with antipsychotic drugs, which are known to have adverse health effects. 

An alarming rise in schizophrenia diagnoses suggests some homes have found a way ...